Omnia SanaPlant Comparison
Eyebright vs Goldenseal
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Eyebright and Goldenseal: they share 6 indicated uses (arthritis / joint pain, diarrhoea, infection (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Eyebright | Goldenseal | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 5/10 | Stronger for Goldenseal |
| Diarrhoea | 1/10 | 5/10 | Stronger for Goldenseal |
| Infection (general) | 2/10 | 5/10 | Stronger for Goldenseal |
| Inflammation (general) | 2/10 | 5/10 | Stronger for Goldenseal |
| Skin irritation | 1/10 | 5/10 | Stronger for Goldenseal |
| Wounds | 1/10 | 5/10 | Stronger for Goldenseal |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Give the plant its anti-inflammatory action on irritated tissue.
Berberine is the main antimicrobial, hypoglycaemic and hypolipidaemic constituent. Notably, whole-leaf extracts are more potent against MRSA than isolated berberine (owing to efflux-pump-inhibitory flavonoids) and show quorum-quenching, anti-virulence activity.
Pharmacological Actions
Astringent and anti-inflammatory for eye irritation, redness and conjunctivitis (traditional, as an eye compress or bath) - an open prospective cohort of Euphrasia single-dose eye drops reported recovery or clear improvement in most patients with conjunctivitis
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Traditional & Indicated Uses
Eases eye strain and watery, itchy eyes from allergy (hay fever / allergic conjunctivitis)
inferred from anti-inflammatory action
inferred from anticancer action
Soothes upper-respiratory catarrh and mild infection (traditional)
Astringent and anti-inflammatory for eye irritation, redness and conjunctivitis (traditional, as an eye compress or bath) - an open prospective cohort of Euphrasia single-dose eye drops reported recovery or clear improvement in most patients with conjunctivitis; Eases eye strain and watery, itchy eyes from allergy (hay fever / allergic conjunctivitis)
Eases eye strain and watery, itchy eyes from allergy (hay fever / allergic conjunctivitis)
Soothes upper-respiratory catarrh and mild infection (traditional)
inferred from anti-inflammatory action
Soothes upper-respiratory catarrh and mild infection (traditional)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Digestive / gastrointestinal support (traditional for dyspepsia and ulcers)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat; Topical for skin infections and irritation - whole-leaf extract is active in vitro against methicillin-resistant Staphylococcus aureus (MRSA)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth); Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Safety, Cautions & Contraindications
CRITICAL: do not put non-sterile, homemade eyebright preparations directly into the eye - this risks serious eye infection. Use only commercially prepared sterile products in the eye, or apply a strained, cooled infusion as a compress over closed eyelids.
Traditional use only; persistent eye symptoms, pain, discharge or vision change need assessment by an eye-care professional. Safety in pregnancy and breastfeeding is not established.
Contraindicated in pregnancy and breastfeeding: berberine crosses the placenta and into milk and can cause or worsen newborn jaundice (risk of kernicterus); do not give to infants.
Berberine strongly inhibits drug-metabolising enzymes (especially CYP3A4 and CYP2D6), so it can raise the blood levels of many medicines - a significant herb-drug-interaction risk. In a screen of commercial herbal products, goldenseal was among the most potent CYP2D6 inhibitors and also inhibited CYP3A4. High doses have shown possible liver, nerve and photo-toxicity.
External Ids
Botanical Description
Small, semi-parasitic annual herb (drawing some nutrients from the roots of neighbouring grasses) with tiny, opposite, toothed leaves and delicate, two-lipped white to pale lilac flowers marked with purple veins and a yellow throat spot, giving a bright, eye-like appearance that inspired both its common and Latin names.[11]
Low, woodland perennial herb rising from a knotted, bright yellow rhizome with wiry yellow roots. Each stem bears two ragged, palmately lobed, maple-like leaves and a single small, inconspicuous greenish-white flower, followed by a raspberry-like cluster of red berries.[1]
Habitat
Grows in short, unimproved grassland, pastures, meadows and dunes on well-drained soils, always in association with grasses on which it partially parasitises; native to Europe.[11]
Grows in rich, shaded deciduous woodland with humus-rich soil; native to eastern North America, now scarce in the wild due to overharvesting and largely supplied by cultivation.[1]
Harvesting
The flowering aerial parts are cut in summer while in flower and dried in a warm, shaded, airy place.[11]
The rhizome and root are dug in autumn from plants at least three to four years old, when berberine content is highest, then cleaned and dried; because wild populations are depleted, cultivated or sustainably sourced material is strongly preferred, and careful identification against the toxic mayapple and bloodroot, which share its woodland habitat, is essential before any wild-harvesting.[1]
Traditional Uses
Goldenseal root has a Native American and, after adoption by Eclectic physicians, wider North American tradition as a bitter tonic and antimicrobial remedy for mucous-membrane infections, sore throat, digestive upset and topical skin infections, directly reflecting its high berberine content.[1]
Preparations
Strained, cooled infusion applied as a compress over closed eyelids, or used (only when sterile, commercially prepared) as an eyewash for irritated or red eyes.
Commercially prepared, sterile Euphrasia eye drops used for conjunctivitis; a prospective clinical cohort found improvement in most users.
Dried rhizome and root simmered in water as a traditional bitter antimicrobial tea, or used as a gargle for sore throat.
Tincture 1:10 in 60% ethanol of the dried rhizome and root, 2-4 ml three times daily per the WHO monograph Rhizoma Hydrastis. Educational reference only, not a prescription.
Extract standardised to berberine/hydrastine content, taken as capsules; whole-leaf extracts have shown stronger antimicrobial activity than isolated berberine in some studies.
Dosage
No dose is given here because no official posology exists. The HMPC assessed eyebright and DECLINED to establish a herbal monograph, concluding that the efficacy of the claimed uses is undocumented and that external eye application of ex tempore (home-prepared) preparations is 'not hygienic and not safe', so therapeutic use cannot be recommended. Traditional sources describe a strained, cooled infusion used as a compress, but that is precisely the practice the HMPC advised against; nothing home-prepared should be put in or on the eye. Educational reference only, not a prescription.
The WHO monograph on Rhizoma Hydrastis gives a daily dose of 0.5-1.0 g of the dried rhizome and root three times, or taken as a decoction; a 1:1 liquid extract in 60% ethanol at 0.3-1.0 mL three times; or a 1:10 tincture in 60% ethanol at 2-4 mL three times. For short-term use only, given goldenseal's potent CYP-enzyme inhibition and its contraindication in pregnancy. Educational reference only, not a prescription.
References
Lookalikes Review
Drug Class Interactions
Not documented
Dangerous Lookalikes
Not documented
References & Sources
- Novy, P., Davidova, H., Serrano-Rojero, C.S., Rondevaldova, J. et al (2015) 'Composition and Antimicrobial Activity of Euphrasia rostkoviana Hayne Essential Oil', Evidence-Based Complementary and Alternative Medicine, 2015, pp. 734101. doi:10.1155/2015/734101 Preclinical
https://doi.org/10.1155/2015/734101 - D'Ambrosio, M., Ciocarlan, A. and Aricu, A (2020) 'Minor acetylated metabolites from Euphrasia rostkoviana', Natural Product Research, 34(2), pp. 290-295. doi:10.1080/14786419.2018.1530227 Preclinical
https://doi.org/10.1080/14786419.2018.1530227 - Ververis, A., Kyriakou, S., Paraskeva, H., Panayiotidis, M.I. et al (2024) 'Chemical Characterization and Assessment of the Neuroprotective Potential of Euphrasia officinalis', International Journal of Molecular Sciences, 25(23), pp. 12902. doi:10.3390/ijms252312902 Preclinical
https://doi.org/10.3390/ijms252312902 - Meier-Girard, D., Gerstenberg, G., Stoffel, L., Kohler, T., Klein, S.D., Eschenmoser, M., Mitter, V.R., Nelle, M. and Wolf, U (2020) 'Euphrasia eye drops in preterm neonates with ocular discharge: a randomized double-blind placebo-controlled trial', Frontiers in Pediatrics, 8, pp. 449. doi:10.3389/fped.2020.00449 Randomized trial
https://doi.org/10.3389/fped.2020.00449 - Liu, Y., Hwang, E., Ngo, H.T.T., Perumalsamy, H., Kim, Y.J., Li, L. and Yi, T.H (2018) 'Protective effects of Euphrasia officinalis extract against ultraviolet B-induced photoaging in normal human dermal fibroblasts', International Journal of Molecular Sciences, 19(11), pp. 3327. doi:10.3390/ijms19113327 Preclinical
https://doi.org/10.3390/ijms19113327 - Porchezhian, E., Ansari, S.H. and Shreedharan, N.K (2000) 'Antihyperglycemic activity of Euphrasia officinale leaves', Fitoterapia, 71(5), pp. 522-526. doi:10.1016/s0367-326x(00)00204-5 Preclinical
https://doi.org/10.1016/s0367-326x(00)00204-5 - Sticher, O. and Salama, O (1981) 'Iridoid glucosides from Euphrasia rostkoviana', Planta Medica, 42(6), pp. 122-123. doi:10.1055/s-2007-971584 Preclinical
https://doi.org/10.1055/s-2007-971584 - Lorenz, P., Knittel, D.N., Conrad, J., Lotter, E.M., Heilmann, J., Stintzing, F.C. and Kammerer, D.R (2016) '1-Acetyl-3-[(3R)-hydroxyfatty acyl]glycerols: lipid compounds from Euphrasia rostkoviana Hayne and E. tetraquetra (Breb.) Arrond', Chemistry & Biodiversity, 13(5), pp. 602-612. doi:10.1002/cbdv.201500233 Preclinical
https://doi.org/10.1002/cbdv.201500233 - Gawenda-Kempczynska, D., Olech, M., Balcerek, M., Nowak, R., Zaluski, T. and Zaluski, D (2022) 'Phenolic acids as chemotaxonomic markers able to differentiate the Euphrasia species', Phytochemistry, 203, pp. 113342. doi:10.1016/j.phytochem.2022.113342 Preclinical
https://doi.org/10.1016/j.phytochem.2022.113342 - Benedec, D., Oniga, I., Hanganu, D., Vlase, A.M., Ielciu, I., Crisan, G., Fit, N., Niculae, M., Bab, T., Pall, E. and Vlase, L (2024) 'Revealing the Phenolic Composition and the Antioxidant, Antimicrobial and Antiproliferative Activities of Two Euphrasia sp. Extracts', Plants, 13(13), pp. 1790. doi:10.3390/plants13131790 Preclinical
https://doi.org/10.3390/plants13131790 - Herbal Reality (n.d.) 'Eyebright (Euphrasia officinalis): Benefits, Uses, Safety'. Available at: https://www.herbalreality.com/herb/eyebright/ Traditional / reference
https://www.herbalreality.com/herb/eyebright/ - Paduch, R. and colleagues (2014) 'Assessment of Eyebright (Euphrasia officinalis L.) Extract Activity in Relation to Human Corneal Cells Using In Vitro Tests'. doi:10.5152/balkanmedj.2014.8377 Traditional / reference
https://doi.org/10.5152/balkanmedj.2014.8377 - Stoss, M., Michels, C., Peter, E., Beutke, R. and Gorter, R.W (2000) 'Prospective cohort trial of Euphrasia single-dose eye drops in conjunctivitis', Journal of Alternative and Complementary Medicine, 6(6), pp. 499--508. doi:10.1089/acm.2000.6.499 Clinical study
https://doi.org/10.1089/acm.2000.6.499 - European Medicines Agency (HMPC) (2010) 'Public statement on Euphrasia officinalis L. and Euphrasia rostkoviana Hayne, herba'. Available at: https://www.ema.europa.eu/en/documents/herbal-report/final-public-statement-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-report/final-public-statement-euphrasia-officinalis-l-and-euphrasia-rostkoviana-hayne-herba_en.pdf
- Mandal, S.K., Maji, A.K., Mishra, S.K., Ishfaq, P.M., Devkota, H.P., Silva, A.S. and Das, N (2020) 'Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues', Pharmacological Research. doi:10.1016/j.phrs.2020.105085 Randomized trial
https://doi.org/10.1016/j.phrs.2020.105085 - Corn, J., Tibbitts, D., Ito, H., Schafer, M. and Vasilevsky, N (2021) 'Effects of Hydrastis Canadensis, Commiphora Habessinica, Phytolacca Americana, and Echinacea Purpurea on Bacterial Growth', Alternative Therapies in Health and Medicine, 27(4), pp. 24-27. Preclinical
https://scholar.google.com/scholar?q=Effects%20of%20Hydrastis%20Canadensis%2C%20Commiphora%20Habessinica%2C%20Phytolacca%20Americana%2C%20and%20Echinacea%20Purpurea%20on%20Bacterial%20Growth - Ettefagh, K.A., Burns, J.T., Junio, H.A., Kaatz, G.W. and Cech, N.B (2010) 'Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition', Planta Medica, 77(8), pp. 835-840. doi:10.1055/s-0030-1250606 Preclinical
https://doi.org/10.1055/s-0030-1250606 - Cech, N.B., Junio, H.A., Ackermann, L.W., Kavanaugh, J.S. and Horswill, A.R (2012) 'Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA)', Planta Medica, 78(14), pp. 1556--1561. doi:10.1055/s-0032-1315042 Traditional / reference
https://doi.org/10.1055/s-0032-1315042 - Mahady, G.B., Pendland, S.L., Stoia, A. and Chadwick, L.R (2003) 'In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis', Phytotherapy Research, 17(3), pp. 217-221. doi:10.1002/ptr.1108 Preclinical
https://doi.org/10.1002/ptr.1108 - Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., Burns, J.T., Micko, K.T., Graf, T.N., Richter, S.J., Cannon, R.E., Oberlies, N.H. and Cech, N.B (2011) 'Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis)', Journal of Natural Products, 74(7), pp. 1621-1629. doi:10.1021/np200336g Preclinical
https://doi.org/10.1021/np200336g - Britton, E.R., Kellogg, J.J., Kvalheim, O.M. and Cech, N.B (2017) 'Biochemometrics to Identify Synergists and Additives from Botanical Medicines: A Case Study with Hydrastis canadensis (Goldenseal)', Journal of Natural Products, 81(3), pp. 484-493. doi:10.1021/acs.jnatprod.7b00654 Preclinical
https://doi.org/10.1021/acs.jnatprod.7b00654 - Leyte-Lugo, M., Britton, E.R., Foil, D.H., Brown, A.R., Todd, D.A., Rivera-Chavez, J., Oberlies, N.H. and Cech, N.B (2017) 'Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal (Hydrastis canadensis)', Phytochemistry Letters, 20, pp. 54-60. doi:10.1016/j.phytol.2017.03.012 Preclinical
https://doi.org/10.1016/j.phytol.2017.03.012 - Gurley, B.J., Swain, A., Hubbard, M.A., Hartsfield, F., Thaden, J., Williams, D.K., Gentry, W.B. and Tong, Y (2007) 'Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo', Clinical Pharmacology and Therapeutics, 83(1), pp. 61-69. doi:10.1038/sj.clpt.6100222 Randomized trial
https://doi.org/10.1038/sj.clpt.6100222 - Wallace, E.D., Oberlies, N.H., Cech, N.B. and Kellogg, J.J (2018) 'Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics', Food and Chemical Toxicology, 120, pp. 439-447. doi:10.1016/j.fct.2018.07.033 Preclinical
https://doi.org/10.1016/j.fct.2018.07.033 - Douglas, J.A., Follett, J.M., Parmenter, G.A., Sansom, C.E., Perry, N.B. and Littler, R.A (2010) 'Seasonal variation of biomass and bioactive alkaloid content of goldenseal, Hydrastis canadensis', Fitoterapia, 81(7), pp. 925-928. doi:10.1016/j.fitote.2010.06.006 Preclinical
https://doi.org/10.1016/j.fitote.2010.06.006 - Singh, S., Pathak, N., Fatima, E. and Negi, A.S (2021) 'Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine', European Journal of Medicinal Chemistry. doi:10.1016/j.ejmech.2021.113839 Preclinical
https://doi.org/10.1016/j.ejmech.2021.113839 - World Health Organization (2007) 'Rhizoma Hydrastis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Sevior, D.K., Hokkanen, J., Tolonen, A., Abass, K., Tursas, L., Pelkonen, O. and Ahokas, J.T (2010) 'Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail', Xenobiotica, 40(4), pp. 245--254. doi:10.3109/00498251003592683 Preclinical
https://doi.org/10.3109/00498251003592683 - Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Khan, I.A. and Shah, A (2005) 'In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes', Clinical Pharmacology and Therapeutics, 77(5), pp. 415-426. doi:10.1016/j.clpt.2005.01.009 Randomized trial
https://doi.org/10.1016/j.clpt.2005.01.009 - McDonald, M.G., Tian, D.D., Thummel, K.E., Paine, M.F. and Rettie, A.E (2020) 'Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects', Drug Metabolism and Disposition, 48(10), pp. 1018-1027. doi:10.1124/dmd.120.091041 Preclinical
https://doi.org/10.1124/dmd.120.091041 - Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y. and Liu, W.J (2021) 'The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials', Oxidative Medicine and Cellular Longevity, 2021, pp. 2074610. doi:10.1155/2021/2074610 Meta-analysis / review
https://doi.org/10.1155/2021/2074610 - Forest Farming (Cooperative Extension) 'Goldenseal (Hydrastis canadensis L.)'. Available at: https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ Traditional / reference
https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ - Frasca, T. and Brett, A.S. and Yoo, S.D (1997) 'Mandrake toxicity. A case of mistaken identity', Archives of Internal Medicine, 157(17), pp. 2007-9. doi:10.1001/archinte.157.17.2007 Clinical study
https://doi.org/10.1001/archinte.157.17.2007 - North Carolina Extension Gardener Plant Toolbox 'Sanguinaria canadensis (Bloodroot)'. Available at: https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/ Traditional / reference
https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.